References
- Kim S, Kim D J, Geyer M A, Howell S B. Multivesicular liposomes containing 1-β-d-arabinofuranosylcytosine for slow-release intrathecal therapy. Cancer Res 1987; 47: 3935–3937
- Kim S, Chatelut E, Kim J C, Howell S B, Cates C, Kormanik P A, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 1993; 11: 2186–2193
- Chamberlain M C, Kormanik P, Howell S B, Kim S. Pharmacokinetics of intralumbar DTC 101 for the treatment of leptomeningeal metastases. Arch Neurol 1995; 52: 912–917
- Bomgaars L, Geyer J R, Franklin J, Dahl G, Park J, Winick N J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 2004; 22: 3916–3921
- Zimm S, Collins J M, Miser J, Chatterji D, Poplack D G. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 1984; 35: 826–830
- Phuphanich S, Maria B, Braeckman R, Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 2007; 81: 201–208
- Glantz M J, Jaeckle K A, Chamberlain M C, Phuphanich S, Recht L, Swinnen L J, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999; 5: 3394–3402
- McClune B, Buadi F K, Aslam N, Przepiorka D. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma 2007; 48: 1849–1851
- Glantz M J, LaFollette S, Jaeckle K A, Shapiro W, Swinnen L, Rozental J R, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17: 3110–3116
- Jaeckle K A, Phuphanich S, van den bent M J, Aiken R, Batchelor T, Campbell T, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001; 84: 157–163
- Jaeckle K A, Batchelor T, O'Day S J, Phuphanich S, New P, Lesser G, et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002; 57: 231–239
- Sancho J M, Ribera J M, Romero M J, Martin-Reina V, Giraldo P, Ruiz E. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases. Haematologica 2006; 91: ECR02
- Benesch M, Sovinz P, Krammer B, Lackner H, Mann G, Schwinger W, et al. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 2002; 29: 222–226
- Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. J Clin Oncol 2007; 109: 3214–3218